Claes, Marijke

Fanning, G

Lenz, O

Neyts, Johan

Simmen, K

Van Marck, H

Vandenbroucke, I

Verbinnen, T

Vijgen, L

English

Research Papers in Economics

A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PLoS Comput.

A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations.

Accuracy in ampliﬁcation.

Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNAdependent RNA polymerase of the hepatitis C virus. Adv. Drug Deliv.

Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors. Gastroenterology 135:1710–1718.e2.

BMS-790052 is a ﬁrst-in-class potent hepatitis C virus (HCV) NS5A inhibitor for patients with chronic HCV infection: results from a proof-ofconcept study. Hepatology 48:1025A.

Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance.

Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res.

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 50:1709–1718.

Clonal interference and the evolution of RNA viruses.

Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing.

Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates. Antiviral Res.

Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors.

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.

Estimating the future health burden of chronic hepatitis C and human immunodeﬁciency virus infections in the United States.

Genetic variability and diversity of intracellular genome-length hepatitis C virus RNA in long-term cell culture.

GT-1a or GT-1b subtype-speciﬁc resistance proﬁles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob. Agents Chemother.

Hepatitis C viral dynamics in vivo and the antiviral efﬁcacy of interferon-alpha therapy.

Hepatitis C virus drug resistance and immunedriven adaptations: relevance to new antiviral therapy. Hepatology 49:1069–

Identiﬁcation and analysis of ﬁtness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res.

Induced-ﬁt binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/ NS4A protease target.

Lost in translation: implications of HIV-1 codon usage for immune escape and drug resistance.

Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients signiﬁcantly impact treatment outcomes.

Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PLoS One 4:e6079.

Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.

Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations.

Memory in viral quasispecies.

Minor variant detection at different template concentrations in HIV-1 phenotypic and genotypic tropism testing. Open Virol.

Minority human immunodeﬁciency virus type 1 variants in antiretroviralnaive persons with reverse transcriptase codon 215 revertant mutations.

Mutation rates among RNA viruses.

Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.

Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro.

Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication ﬁtness and partial rescue by second-site mutations.

Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48:1769–1778.

Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology 370:237–245.

Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population.

Rapid emergence of protease inhibitor resistance in hepatitis C virus.

Rates of evolutionary change in viruses: patterns and determinants.

Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors.

Relative replication capacity and selective advantage proﬁles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrob. Agents Chemother.

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.

Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus.

Retracing the evolutionary pathways of human immunodeﬁciency virus type 1 resistance to protease inhibitors: virus ﬁtness in the absence and in the presence of drug.

Role of minority populations of human immunodeﬁciency virus type 1 in the evolution of viral resistance to protease inhibitors.

Sequence variation of NS3/4A in HCV replicons exposed to ITMN-191 concentrations encompassing those likely to be achieved following clinical dosing.

Temporal dynamics of a predominant protease inhibitor-resistance mutation in a treatment-naive, hepatitis C virus-infected individual.

The 30th anniversary of quasispecies. Meeting on ‘Quasispecies: past, present and future.’

The emerging ﬁeld of HCV drug resistance.

The error threshold. Virus Res.

The role of alternative genetic codes in viral evolution and emergence.

Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients.

Viral resistance to speciﬁcally targeted antiviral therapies for hepatitis C (STAT-Cs).

Why are there different dynamics in the selection of drug resistance

Tracking the evolution of multiple in vitro HCV replicon mutants under protease inhibitor selection pressure by 454 ultra deep sequencing.

https://lirias.kuleuven.be/bitstream/123456789/274277/2/2010160.pdf

Tracking the evolution of multiple in vitro HCV replicon mutants under protease inhibitor selection pressure by 454 ultra deep sequencing.

Abstract

Similar works

Full text

Available Versions

Research Papers in Economics